Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States.
The last earnings update was 35 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Spero Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Spero Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Spero Therapeutics's earnings are expected to grow by 9.2% yearly, however this is not considered high growth (20% yearly).
Spero Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Spero Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Spero Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Spero Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Spero Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Spero Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Spero Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Ankit Mahadevia, MD, MBA serves as the Chief Executive Officer and President of Spero Therapeutics, LLC. Mr. Mahadevia Co-founded of Spero Therapeutics, Inc. in 2013 and has been its Chief Executive Officer and President since March 2015. He serves as an Atlas Advisor at Atlas Venture L.P. He co-founded Synlogic, Inc. and served as its President. He served as Entrepreneur-In-Residence at Atlas Venture L.P. Mr. Mahadevia joined Atlas Venture in 2008 and focused on other medical technologies that met a significant unmet clinical need. He also served as a Principal at Atlas Venture. He served as Acting CBO at Spero Therapeutics, Inc. He serves as the Chief Business Officer of Rodin Therapeutics Inc. He is also actively involved in the Shire/Atlas Venture Alliance and the Atlas/Monsanto Seed Fund Alliance. Mr. Mahadevia was a Venture Partner in the life sciences group at Atlas Venture in Cambridge, Massachusetts, where he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, including Synlogic Therapeutics and Translate Bio. He has led three of these companies as acting or full-time CEO. He works closely with Arteaus Therapeutics and JenaValve. He worked with Sirion Therapeutics. Prior to joining Atlas Venture in 2008, Mr. Mahadevia worked on product and business development with the founding team at Arcion Therapeutics, Inc. Before that, he held positions in Business Development at Genentech, Inc. and Vanda Pharmaceuticals, Inc. Mr. Mahadevia also served clients in the health services sector at McKinsey & Company, Inc. He also served as a Consultant at Monitor Group, where he supported clients in the biotechnology and medical device industries on strategy, marketing and business development. Mr. Mahadevia held roles in the U.S. Government Accountability Office. He has been a Director at Spero Therapeutics, Inc. since September 2013. He serves as a Director of Annovation Biopharma and Fibrex Medical Research & Development GesmbH. He serves as a Board Observer at Resolvyx Pharmaceuticals and Nimbus Discovery. He served as a Director of Lumavita AG. He served as Director at Synlogic, Inc. since July 22, 2014 until July 18, 2016. He served as a Director of RaNA Therapeutics, Inc. (now known as Translate Bio, Inc.). He is a Reviewer for the National Cancer Institute SBIR Bridge Awards. He also serves on the board of the Johns Hopkins Technology Alliance/Johns Hopkins Alliance for Technology Transfer. Dr. Mahadevia began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor and the Mexican Institute of Social Security. He served as a Board Observer at Molecular Biometrics, Inc. He was appointed by the U.S. Secretary of Health and Human Services to the Advisory Council of the NIH Center for Advancing Translational Sciences. During his medical training, he published research in glaucoma therapy and neurovascular interventions. Mr. Mahadevia completed his M.D. from Johns Hopkins University School of Medicine and his M.B.A. from the Wharton School at the University of Pennsylvania. He graduated summa cum laude with a B.A. in Economics and Biology from Northwestern University.
Ankit's compensation has increased whilst company is loss making.
Ankit's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Spero Therapeutics management team is less than 2 years, this suggests a new team.
CFO & Treasurer
Chief Operating Officer
Chief Scientific Officer
Director of Investor Relations
Head of People Strategy & Culture
Senior Vice President of Development
Chief Medical Officer
Head of Clinical Microbiology
Head of Clinical Operations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Spero Therapeutics board of directors is about average.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. has collaboration with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries, as well as has option to rights to SPR741 in the territory. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.